Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma
Por:
Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G
Publicada:
1 ene 2024
Ahead of Print:
1 oct 2023
Resumen:
Introduction: The risk of relapse in retinoblastoma is currently determined by the presence of high-risk histopathologic factors in the enucleated eye. However, the probability of developing metastatic disease is heterogeneous among these patients. Evaluating a biological marker to identify high-risk patients could be useful in clinical setting. This study aims to evaluate whether the expression of TFF1, a surrogate for subtype 2 retinoblastoma, is a prognostic marker for relapse and death.Methods: This multicenter cohort study included 273 patients, 48 of whom had extraocular disease. Immunohistochemical staining were performed for CRX, ARR3, TFF1, and Ki67. Tumors were classified as histological subtype 1 (HS1) if they had low or no expression of TFF1 (quick score (QS) <= 50) and as histological subtype 2 (HS2) if they expressed TFF1 diffusely (QS > 50). We studied the association between HS classification and outcome.Results: Of 273 patients, 35.9% were classified as HS1, 59.3% as HS2 and 4.8% were not evaluable. In multivariate analysis, patients with HS2 tumors had a higher probability of relapse and death than those with HS1 (p < .0001 and p = .00020, respectively). We identified a higher-risk subgroup among HS2 tumors, presenting non-mutually exclusive expression of ARR3 and TFF1 and had an increased risk of relapse and death compared with tumors that displayed mutually exclusive expression (p = .012 and p = .027, respectively).Conclusions: Expression of TFF1, especially when it is not-mutually exclusive with ARR3, is an independent significant marker of poor outcome in retinoblastoma.
Filiaciones:
Aschero MR:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Ganiewich D:
Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina
Lamas G:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Restrepo-Perdomo CA:
Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain
Ottaviani D:
SIREDO Center, Institut Curie and University Paris Cité, Paris, France
Zugbi S:
National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Camarero S:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Néspoli E:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Cuadrado-Vilanova M:
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pérez-Jaume S:
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Pascual-Pastó G:
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Sampor C:
Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Grigorovski N:
Department of Pediatric Oncology, Clinical Division, National Institute of Cancer, Rio de Janeiro, Brazil
Salas B:
Department of Pediatric Oncology, Hospital del Niño Manuel A. Villarroel, Cochabamba, Bolivia
Suñol M:
Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain
Carcaboso AM:
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Mora J:
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
de Dávila MTG:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Doz F:
SIREDO Center, Institut Curie and University Paris Cité, Paris, France
Radvanyi F:
SIREDO Center, Institut Curie and University Paris Cité, Paris, France
Abramson DH:
Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Llera AS:
National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina
Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina
Schaiquevich PS:
National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Lubieniecki F:
Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina
Chantada G:
National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain
Institut de Recerca Sant Joan de Déu, Barcelona, Spain
Hematology Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay
Green Submitted
FULL TEXT
 |
Accepted Version |
https://www.wiley.com/en-us/network/publishing/research-publishing/open-access/copyright-and-licensing-with-wiley |
|
|